Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials
- Bhavna Oza 1, Eleni Frangou 1, Tim Eisen 2, Grant D Stewart 3, Axel Bex 4,5, David Harrison 6, Mahesh K B Parmar 1, Ruth Langley 1, Duncan Gilbert 1, Angela Meade 1
- Bhavna Oza 1, Eleni Frangou 1, Tim Eisen 2
- 1MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
- 2Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
- 3Department of Surgery, Addenbrooke's Hospital, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
- 4UCL Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, London, UK.
- 5Netherlands Cancer Institute, Amsterdam, The Netherlands.
- 6School of Medicine, University of St Andrews, St Andrews, UK.
- 0MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Histological subtype of renal cell carcinoma (RCC) impacts relapse timing and patterns. Papillary RCC and sarcomatoid RCC patients experiencing abdominal recurrence have poorer outcomes, suggesting tailored surveillance strategies. Clear-cell RCC and chromophobe RCC show different relapse characteristics.
Area Of Science
- Urology
- Oncology
- Nephrology
Background
- Outcomes for intermediate- and high-risk renal cell carcinoma (RCC) based on histological subtype are not well-defined.
- Histology is crucial for predicting survival and informing surveillance after nephrectomy for RCC.
Purpose Of The Study
- To determine the prognostic value of RCC histology in predicting survival.
- To inform surveillance strategies by analyzing patterns of first recurrence based on RCC subtype.
Main Methods
- Pooled data from two phase 3 trials (SORCE and ASSURE) involving 3542 patients with RCC.
- Classified patients into clear-cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chRCC), and sarcomatoid RCC (sRCC).
- Analyzed relapse rates, time to relapse (TTR), and first relapse sites using multivariable Cox regression models.
Main Results
- Papillary RCC (pRCC) and clear-cell RCC (ccRCC) showed similar overall survival.
- Median time to relapse (TTR) was significantly shorter for pRCC (1.34 yr) compared to ccRCC (1.78 yr).
- Sarcomatoid RCC (sRCC) had the shortest TTR (0.74 yr), while chromophobe RCC (chRCC) had the longest (2.72 yr). Abdominal recurrence in sRCC and pRCC was associated with poorer survival.
Conclusions
- Intermediate and high-risk pRCC patients relapse earlier than ccRCC patients.
- Abdominal recurrence in pRCC and sRCC indicates poor prognosis, suggesting enhanced abdominal imaging for early detection.
- chRCC has a favorable prognosis, potentially allowing for delayed image-based surveillance.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

